Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2023–2026. doi: 10.1128/aac.39.9.2023

Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

S Merali 1, K Chin 1, L Del Angel 1, R W Grady 1, M Armstrong 1, A B Clarkson Jr 1
PMCID: PMC162875  PMID: 8540710

Abstract

The iron-chelating drug deferoxamine (DFO) has been shown to be active in animal models of Pneumocystis carinii pneumonia (PCP), with effective daily intraperitoneal bolus dosages being 400 and 1,000 mg of DFO mesylate kg of body weight-1 in mouse and rat models, respectively. Continuous infusion produced a moderately improved response in a rat model. The data reported here demonstrate that the response achieved by continuous infusion of 195 and 335 mg of DFO mesylate kg-1 day-1 in the rat model is associated with mean concentrations in plasma of 1.3 and 2.5 micrograms of DFO ml-1 and mean concentrations in lung tissue of 4.9 and 6.0 micrograms of DFO g of lung tissue-1, respectively. Since current clinical use of DFO mesylate for the treatment of iron overload produces higher concentrations in the plasma of patients, DFO may prove to be a useful anti-PCP treatment. The 2.4- to 3.8-fold higher DFO concentration observed in lung tissue compared with that observed in plasma may be important in the response of PCP to DFO.

Full Text

The Full Text of this article is available as a PDF (183.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angel M. F., Narayanan K., Swartz W. M., Ramasastry S. S., Kuhns D. B., Basford R. E., Futrell J. W. Deferoxamine increases skin flap survival: additional evidence of free radical involvement in ischaemic flap surgery. Br J Plast Surg. 1986 Oct;39(4):469–472. doi: 10.1016/0007-1226(86)90115-3. [DOI] [PubMed] [Google Scholar]
  2. Bowern N., Ramshaw I. A., Badenoch-Jones P., Doherty P. C. Effect of an iron-chelating agent on lymphocyte proliferation. Aust J Exp Biol Med Sci. 1984 Dec;62(Pt 6):743–754. doi: 10.1038/icb.1984.70. [DOI] [PubMed] [Google Scholar]
  3. Bradley B., Prowse S. J., Bauling P., Lafferty K. J. Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes. 1986 May;35(5):550–555. doi: 10.2337/diab.35.5.550. [DOI] [PubMed] [Google Scholar]
  4. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davey R. T., Jr, Masur H. Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Apr;34(4):499–504. doi: 10.1128/aac.34.4.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fudman E. J., Till G. O., Fox I. H. Deferoxamine induced decreases of lipid peroxides in rheumatoid arthritis. J Rheumatol. 1987 Aug;14(4):686–691. [PubMed] [Google Scholar]
  7. Gordeuk V. R., Thuma P. E., Brittenham G. M. Iron chelation therapy for malaria. Adv Exp Med Biol. 1994;356:371–383. doi: 10.1007/978-1-4615-2554-7_39. [DOI] [PubMed] [Google Scholar]
  8. Hershko C. Biological models for studying iron chelating drugs. Baillieres Clin Haematol. 1989 Apr;2(2):293–321. doi: 10.1016/s0950-3536(89)80019-8. [DOI] [PubMed] [Google Scholar]
  9. Hershko C., Pinson A., Link G. Iron chelation. Blood Rev. 1990 Mar;4(1):1–8. doi: 10.1016/0268-960x(90)90011-g. [DOI] [PubMed] [Google Scholar]
  10. Kovacs J. A., Hiemenz J. W., Macher A. M., Stover D., Murray H. W., Shelhamer J., Lane H. C., Urmacher C., Honig C., Longo D. L. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663–671. doi: 10.7326/0003-4819-100-5-663. [DOI] [PubMed] [Google Scholar]
  11. Kruck T. P., Teichert-Kuliszewska K., Fisher E., Kalow W., McLachlan D. R. High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies. J Chromatogr. 1988 Dec 9;433:207–216. doi: 10.1016/s0378-4347(00)80599-x. [DOI] [PubMed] [Google Scholar]
  12. Lee P., Mohammed N., Marshall L., Abeysinghe R. D., Hider R. C., Porter J. B., Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 1993 Jul-Aug;21(4):640–644. [PubMed] [Google Scholar]
  13. Merali S., Chin K., Grady R. W., Weissberger L., Clarkson A. B., Jr Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob Agents Chemother. 1995 Jul;39(7):1442–1444. doi: 10.1128/aac.39.7.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meyer-Brunot H. G., Keberle H. The metabolism of desferrioxamine B and ferrioxamine B. Biochem Pharmacol. 1967 Mar;16(3):527–535. doi: 10.1016/0006-2952(67)90100-1. [DOI] [PubMed] [Google Scholar]
  15. Peto T. E., Thompson J. L. A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron. Br J Haematol. 1986 Jun;63(2):273–280. doi: 10.1111/j.1365-2141.1986.tb05550.x. [DOI] [PubMed] [Google Scholar]
  16. Polson R. J., Jawed A., Bomford A., Berry H., Williams R. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br Med J (Clin Res Ed) 1985 Aug 17;291(6493):448–448. doi: 10.1136/bmj.291.6493.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Singh S., Mohammed N., Ackerman R., Porter J. B., Hider R. C. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection. Anal Biochem. 1992 May 15;203(1):116–120. doi: 10.1016/0003-2697(92)90050-h. [DOI] [PubMed] [Google Scholar]
  18. Summers M. R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol. 1979 Aug;42(4):547–555. doi: 10.1111/j.1365-2141.1979.tb01167.x. [DOI] [PubMed] [Google Scholar]
  19. Weinberg G. A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994 May;38(5):997–1003. doi: 10.1128/aac.38.5.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Weinberg G. A., Shaw M. M. Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro. J Protozool. 1991 Nov-Dec;38(6):223S–224S. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES